Wegovy heart health data is promising — but insurers face long road, high cost to cover obesity drugsThere is likely a long way to go before the U.S. sees increased insurance coverage of obesity drugs, but Novo Nordisk's new data is a meaningful start.[Collection]

There is likely a long way to go before the U.S. sees increased insurance coverage of obesity drugs, but Novo Nordisk's new data is a meaningful start.https://www.cnbc.com/2023/08/09/wegovy-heart-health-data-insurance-hurdles-costs.html